Clinical trials: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
This is a multi-center, open-label, phase I study.
- Trial name
- NCT05247203
- Testing
- Telitacicept, standard therapy
- Where
- 19 sites in China
- Volunteers
- 92 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
This study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the Ascension® MCP.
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis
- Trial name
- MCP (NCT02408471)
- Testing
- Ascension® MCP Finger Implant
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Smith & Nephew, Inc.
Lupus Erythematosus, Systemic
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants.
- Trial name
- RECAST SLE (NCT04925934)
- Testing
- VIB7734
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 214 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus (SLE)
F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA.
- Trial name
- NCT07829614
- Testing
- F182112
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Systemic Lupus Erythematosus (SLE)
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response…
- Trial name
- BENCHMARK-SLE (NCT07175285)
- Testing
- Current standard of care treatment options
- Where
- 70 sites in United States, Argentina and 11 more
- Volunteers
- 223 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus
The primary objective of this study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (SC) CEP-33457 for injection every 4 weeks over 72 weeks (18 doses) in participants with systemic…
- Trial name
- NCT01240694
- Testing
- CEP-33457
- Where
- 85 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Cephalon, Inc.
Systemic Lupus Erythematosus
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
- Trial name
- NCT05123586
- Testing
- LY3361237
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus…
- Trial name
- NCT02514967
- Testing
- Blisibimod
- Where
- 3 sites in Georgia
- Volunteers
- 3 people
- Sponsor
- Anthera Pharmaceuticals
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells.
- Conditions
- Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
- Trial name
- NCT06265220
- Testing
- AB-101, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Systemic Lupus Erythematosus
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
- Trial name
- PLUTO (NCT01649765)
- Testing
- Belimumab 10 mg/kg
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Systemic
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
A Study to Investigate the Tolerability, Safety,Pharmacokinetics and efficacy of GR1603 in subjects with Systemic Lupus Erythematosus ； GR1603 injection is a monoclonal antibody targeting IFNAR1, which can block IFNAR binding to…
- Trial name
- NCT06015230
- Testing
- low dose GR1603 in phase Ⅰb, high dose GR1603 in phaseⅠb, low dose GR1603 in phase Ⅱ
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Systemic Lupus Erythematosus
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT03252587
- Testing
- BMS-986165
- Where
- 192 sites in United States, Argentina and 15 more
- Volunteers
- 363 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
This is a Phase III, randomized, double blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo when combined with a single stable background…
- Trial name
- BEGIN (NCT00539838)
- Testing
- Prednisone, Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate), Methylprednisolone
- Volunteers
- 33 people
- Sponsor
- Genentech, Inc.
Systemic Lupus Erythematosus
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus…
- Trial name
- SIRIUS-SLE 2 (NCT05624749)
- Testing
- ianalumab
- Where
- 90 sites in United States, Argentina and 13 more
- Volunteers
- 288 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Lupus Nephritis
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
- Trial name
- NCT05268289
- Testing
- Iptacopan (part 1), Iptacopan (part 2)
- Where
- 74 sites in United States, Argentina and 17 more
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Systemic Lupus Erythematosus
Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)
Women with Systemic Lupus Erythematosus (SLE) are prone to cardiovascular disease. Early detection of improvement of endothelial function with simvastatin could be a clue for future intervention trials.
- Trial name
- NCT00739050
- Testing
- simvastatin
- Volunteers
- 4 people
- Sponsor
- Organon and Co
Systemic Lupus Erythematosus (SLE)
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC…
- Trial name
- NCT06144710
- Testing
- SG301 SC Injection
- Where
- 10 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.